Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425126
Status:
COMPLETED
Last Update Posted:
2010-05-27
First Post:
2007-01-18
Brief Title:
Effect of Procrit Epoetin Alfa on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Sponsor:
West Penn Allegheny Health System
Organization:
West Penn Allegheny Health System
Study Overview
Official Title:
Effect of ProcritEpoetin Alfa on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Delayed graft function DGF is a major complication following deceased donor renal transplantation The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury While not always clinically significant anywhere from 10-50 of transplant patients may develop DGF Ongoing research in animal models has demonstrated benefit with administration of erythropoietin The investigators propose to study the effect of ProcritEpoetin Alfa on delayed graft function in subjects undergoing kidney transplantation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None